CROSSPOINT Therapeutics
PrivateLast Round
VC Round
Mar 4, 2026
Total Funding Raised
$2.82M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
CROSSPOINT Therapeutics is a biotechnology company that develops next-generation antibody therapies using its proprietary Stealth-Body platform to reduce toxicity and side effects.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CROSSPOINT Therapeutics Comparables
Compare CROSSPOINT Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| mAbsolve Ltd. | 91% | |
| Proteinea | 78% | |
| Xencor, Inc. | 69% |
CROSSPOINT Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 4, 2026 | ||||
| Grant | Aug 8, 2024 | ||||
| Seed | Apr 1, 2024 |
CROSSPOINT Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kite Entrepreneurship Foundation | Seed |
| Korea University Holdings | Seed |
| Infobank Corp | Seed |
| Bigbang Angels, Inc. | Seed |
| Korea Omega Investment Corp | Seed |
| Kudos Ventures | VC Round |
| Government of South Korea | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
$2.38M round led by SU Investment Capital and Kudos Ventures.
CROSSPOINT Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CROSSPOINT Therapeutics's valuation, stock price, and market status.
Is CROSSPOINT Therapeutics a public or private company?
CROSSPOINT Therapeutics is a private company.
What is the current stock price of CROSSPOINT Therapeutics?
CROSSPOINT Therapeutics is a private company, so its shares have no public market price. Caplight tracks CROSSPOINT Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CROSSPOINT Therapeutics worth (valuation)?
Valuation information for CROSSPOINT Therapeutics is not publicly available.
Can I buy CROSSPOINT Therapeutics stock?
CROSSPOINT Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CROSSPOINT Therapeutics's last funding round?
CROSSPOINT Therapeutics's most recent funding round was VC Round on March 4, 2026.
Who are the main investors in CROSSPOINT Therapeutics?
Key investors in CROSSPOINT Therapeutics include Kudos Ventures, SU Investment Capital.
Will CROSSPOINT Therapeutics IPO soon?
No public IPO plans have been announced for CROSSPOINT Therapeutics.
How can I track CROSSPOINT Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in CROSSPOINT Therapeutics's shares on secondary markets.